Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825) Article

Wefel, Jeffrey S, Armstrong, Terri S, Pugh, Stephanie L et al. (2021). Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825) . NEURO-ONCOLOGY, 23(7), 1125-1138. 10.1093/neuonc/noab011

Open Access

cited authors

  • Wefel, Jeffrey S; Armstrong, Terri S; Pugh, Stephanie L; Gilbert, Mark R; Wendland, Merideth M; Brachman, David G; Roof, Kevin S; Brown, Paul D; Crocker, Ian R; Robins, H Ian; Hunter, Grant; Won, Minhee; Mehta, Minesh P

sustainable development goals

authors

publication date

  • July 1, 2021

published in

keywords

  • ADJUVANT TEMOZOLOMIDE
  • Clinical Neurology
  • Life Sciences & Biomedicine
  • NORMATIVE DATA
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology
  • glioma
  • neurocognitive function
  • patient-reported outcome

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 1125

end page

  • 1138

volume

  • 23

issue

  • 7